Apellis Pharmaceuticals
APLS
APLS
210 hedge funds and large institutions have $4.55B invested in Apellis Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 73 increasing their positions, 62 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
15% more funds holding
Funds holding: 183 → 210 (+27)
2.12% more ownership
Funds ownership: 84.34% → 86.46% (+2.1%)
1% less call options, than puts
Call options by funds: $82.1M | Put options by funds: $82.8M
Holders
210
Holding in Top 10
11
Calls
$82.1M
Puts
$82.8M
Top Buyers
| 1 | +$131M | |
| 2 | +$94.9M | |
| 3 | +$66.2M | |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$58.4M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$46.5M |
Top Sellers
| 1 | -$98.5M | |
| 2 | -$26.6M | |
| 3 | -$16.3M | |
| 4 |
DM
Deerfield Management
New York
|
-$16.2M |
| 5 |
TLP
Tri Locum Partners
New York
|
-$15M |